• Recruiting

NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Updated: May 26

NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Dara-KPd

DKPD

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma.


Sponsor

Andrew Yee, MD


Collaborators

Amgen

Janssen Research & Development, LLC

 

ClinicalTrials.gov Identifier: NCT04176718


Official Title: A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma


First Posted : November 25, 2019


Click here for ClinicalTrials.gov

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information


Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute

Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Pomalidomide: National Cancer Institute

Pomalidomide : MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Drug: Daratumumab

Drug: Carfilzomib

Drug: Pomalidomide

Drug: Dexamethasone

 

Location

United States, Massachusetts








Posts Archive